ARWR was beaten down once and here is another one
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.
Due your own research and the wise will should agree.
